LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM).1 It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces symmetric demethylation of SmBB’ in MCF-7 cells (IC50 = 25 nM). It reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.WARNING This product is not for human or veterinary use.